CLAIM CARD
A notable tension within the corpus concerns the consistency of oxidative stress outcomes across clinical populations. While Yeung 2015 and Moccia 2019 reported significant reductions in oxidative and inflammatory markers, the clinical RCT in burn patients (Kiani 2024) found no significant effect on its primary malondialdehyde endpoint (P = 0.550). Similarly, Greenlee 2025 observed no clinically concerning pharmacokinetic interference between CoQ10 and doxorubicin, supporting a favorable safety profile in oncology. The disagreement between the clear positive oxidative findings in some cohorts and the null primary result in the burn patient trial may reflect differences in baseline oxidative burden, disease pathology, or the specific biomarker endpoints chosen across studies.
Evidence grade: exploratory
Contradiction status: none
Publication: b8dee5f7-0023-4af5-bacc-446de915555a
Provenance: Derivation Web chain
Citation Support
source_1Xu 2024source_2Spiegeleer 2025source_3Shang 2024source_4Alehagen 2020source_5Phan 2020